Ritlecitinib

Major

Ritlecitinib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Ritlecitinib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Ritlecitinib Simvastatin Flolipid Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Abemaciclib Verzenio Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Acalabrutinib Calquence Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Avapritinib Ayvakit Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Atorvastatin Atorvaliq Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Ritlecitinib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Ritlecitinib Avanafil Stendra Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Bedaquiline Sirturo Increased bedaquiline exposure Details Ritlecitinib Bosutinib Bosulif Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Ritlecitinib Budesonide Entocort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Budesonide Nasal Spray Rhinocort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Budesonide Oral Inhalation Pulmicort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Cobimetinib Cotellic Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Cyclosporine Injection Atopica Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Cyclosporine Ophthalmic Cequa Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Dasatinib Phyrago Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Dihydroergotamine Injection DHE-45® Injection Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Dihydroergotamine Nasal Spray Migranal Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Dofetilide Tikosyn Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Ritlecitinib Encorafenib Braftovi Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Ritlecitinib Entrectinib Rozlytrek Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Ritlecitinib Everolimus Afinitor Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Felodipine Plendil® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Fentanyl Transdermal Patch Duragesic® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Finerenone Kerendia Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Ibrexafungerp Brexafemme Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Ibrutinib Imbruvica Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Ivabradine Corlanor Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Ritlecitinib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Ritlecitinib Lovastatin Altocor® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Lumateperone Caplyta Increased lumateperone exposure and increased risk of lumateperone-related adverse reactions Details Ritlecitinib Lurasidone Latuda Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ritlecitinib Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Ritlecitinib Maraviroc Selzentry Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details